$625M for the Front Door: Oura Is Buying Healthcare's Cheapest Revenue With Its Most Expensive Multiple

Terms are plain: $625 million in cash, subject to purchase price adjustments, with closing expected before the end of 2026. What Oura is buying is a full-stack medical group — a medical AI that answers first, a bench of board-certified physicians who escalate, and a clinician workspace that puts longitudinal records beside wearable trends. Counsel has been answering questions inside the Oura app since June 2026, so this is less a new capability than taking private a care layer already running on Oura's own data.

Oura's own reasoning is about labor, not features: a typical U.S. primary care visit runs about 18 minutes, and the country could be short as many as 86,000 physicians by 2036. The funnel already generates triage — in Oura Labs, 15% of testers who received a symptom radar alert chose to connect to care, more than 10,000 people — and Counsel converts that tap into turning a symptom alert into a prescription, a lab order, or a referral. That is the first time a wearable company has bought the right to act on its own data.

Strip away the wellness framing and this is a trade between two markets priced on opposite ends of the scale. Consumer health data has been valued like software: at the withdrawn IPO range, Oura's roughly $15.6 billion implies about 8.9x fiscal 2026 revenue. Care delivery has been valued like a melting ice cube — Teladoc at 0.72x sales, agilon health at 0.29x. Oura is buying the cheapest layer in healthcare with its most expensive currency, and paying cash because it could not sell the multiple instead.

The read-through is not that telemedicine is cheap. It is that the toll has moved. Whoever holds the first conversation collects the data, sets the price of the visit, and decides who else gets to see the patient. Teladoc and agilon health are priced as interchangeable vendors of virtual minutes and capitated headcounts; Oura is betting they are not, because the front door now carries a sensor. The risk in the trade is equally plain: if the combined business gets valued as care delivery rather than as data, the same 0.7x becomes the multiple Oura pays for itself.

The prize is not the membership fee. From early 2027, Counsel will deliver chronic care management at no cost to eligible Medicare beneficiaries under the CMS ACCESS model, an outcome-aligned payment program run by the Center for Medicare & Medicaid Innovation with more than 160 participating organizations. ACCESS pays for clinical results rather than services delivered — a 10 mmHg blood pressure reduction, for example — and for the 2026-2027 performance period a participant earns full payment only if at least half of its aligned beneficiaries hit every required outcome target.

Oura's gross margin was 55% over the first nine months of fiscal 2026, up from 51% a year earlier — a software-like profile built on subscription revenue. Care delivery is not a software line item: Counsel's costs include physician time, state licensure, malpractice cover and clinical operations. Two rows above are warnings. Hims & Hers Health shows what happens when a consumer subscription business touches fulfillment, watching gross margin fall from 74% to 57% in a year while posting a $66.1 million operating loss in the third quarter despite 49% revenue growth.

agilon health shows the other end of the range, keeping 2.8 cents of every dollar of $6.0 billion in trailing revenue because Medicare medical risk sits inside its cost of revenue. Neither company is a forecast for Oura, and the acquisition can still work. But any model that leaves Oura's blended gross margin near 55% is assuming the care layer costs nothing to run.

The cascade runs one way. A sensor captures the signal; an app turns it into an insight; an AI triages it; a physician acts on it; a measurement device proves the result; a payer pays for it. Oura has owned the second step for years and, as of November 10, owns the third and fourth. That leaves every layer between the patient and the answer either supplier or target.